NorCal SOT
newsletter
February 2009

Letter from the President

We have closed out an eventful year in 2008 – wars, economic depression, long/intense political campaigns and a historic presidential election. With 2009 we have renewed hope and change is afoot. On a personal note, I have been honored to serve as your 2008-2009 President with a dynamic team of NorCal Regional officers. Steve Dizio, who will become our President on May 1st; Tao Wang (NorCal newsletter and website guru), to follow - serving as our current vice-president elect; Sanjay Chanda, a dynamic Past President and Councilor, who has made it his mission to pitch in when ever necessary; hard working Council members Karen Steinmetz and John Wisler; a terrific student representative in Susanne Brander; Jeff Tepper, controlling our purse strings; Chuck Barton, as our Secretary; and a newly created Board position - serving as Postdoc representative - Valerie Mitchell (now with CA EPA).

The NorCal SOT is considered one of the most dynamic Regional Chapters in the SOT with over 300 members. We have had a series of outstanding programs (our last on Safety Pharmacology hosted by Roche – had more than120 attendees). Our next meeting will be hosted by Amgen in South San Francisco on April 23rd 2009. The program will focus on target organ toxicity. Although not fully developed it will be a full day symposium with a minimum of 6 talks; poster session with cash awards; our now popular student function - lunch with the experts; meals all day - include breakfast and lunch; door prizes (wine); and a wonderful opportunity to network and engage in discussions with CROs and consultants. NorCal SOT will also host a join mixer with the Northwest Chapter and UCs Davis and Berkeley at the National SOT meeting in Baltimore at the Hilton hotel, from 6:00 P.M. until 8:00 P.M. on Monday, March 16 - if you are going to Baltimore - please join us in this fun social event.

With Warm Regards,

George R. Clemens

Table of Contents



NorCal SOT newsletter
February 2009

Upcoming Events



NorCal SOT Events at upcoming SOT Annual Meeting

NorCal SOT Regional Chapter Poster

The NorCal SOT Regional Chapter will display a poster at the Graduate Student/Postdoctoral Fellow Mixer at the SOT Annual Meeting in Baltimore. NorCal SOT Board encourages student and postdoctoral members to attend the mixer and of course our poster.

When: Sunday, March 15th from 7:30-8:30 PM

Where: Baltimore Convention Center, Camden Lobby

NorCal SOT, Pacific Northwest SOT, UC Davis and UC Berkeley Joint Reception

When: Monday, March 16, 6:00pm -8:00 pm
Where: Hilton hotel, Key Ballroom 8
What: networking with our colleagues from Pacific Northwest Regional Chapter, announcement of student awards and identification of awardees' mentors, beverage tickets at the door first come first serve, door prize for Livermore wine, hors d'oeuvres, etc. **See you there!!!**

Future NorCal SOT meetings in the Bay area:

NorCal SOT 2009 Spring Meeting **Amgen South SF**
April 23, 2009

Target Organ Toxicity with emphasis on Hepatotoxicity

Morning Session:
Continental Breakfast and Registration:
Dermal Toxicology
Ocular Toxicology
Pulmonary Toxicology
Cardiovascular Toxicology

Afternoon Session: Liver Toxicology
Pathology of the Liver
Building a better biomarker for liver toxicity: New approaches and technologies to identify a better ALT
Role of Perturbed Bile Salt Transport in Hepatotoxicity
Hepatotoxicity Screening

A meeting flyer with detailed information will be distributed soon !!

International Society for Aerosols in Medicine next Congress: Monterey, California, USA, May 10-14, 2009

Dear Colleague,

We are delighted to bring the International Society for Aerosols in Medicine (ISAM) Congress to Monterey (May 10th-14th).

On Sunday May 10th- we will have a workshop on 'Essentials in Inhalation Toxicology' organized by SOT member Ron Wolff.

This workshop will provide the nuts and bolts for the toxicologist to plan and run an inhalation toxicology study including choosing a CRO and meeting regulatory requirements.

Topics
Speaker 1. FDA Expectations
Tim McGovern, PhD, SciLucent, Herndon, VA

Speaker 2. Nuts and Bolts of Planning and Conducting Inhalation Toxicology Studies
Ron Wolff, PhD, DABT Novartis, Emeryville, CA, USA

Speaker 3. Respiratory Physiology Measurements
Juergen Pfeiffer, Nektar Therapeutics, San Carlos, CA USA

Speaker 4, CRO Showcase: 10-min presentations by Inhalation CRO's. (Battelle, Covance, Huntingdon, ITR, IITRI, LRRI, WIL)

The ISAM conference brings together some of the best scientific and clinical minds to communicate their research and address problems associated with aerosols in medicine. Topics for this year's program are: Aerosols in the ICU, Lung clearance, Aerosol therapy for infectious diseases, Cystic Fibrosis, Asthma and COPD: New targets and therapies, Aerosol therapeutics for lung cancer, Vaccines and viruses, Effects of ambient air pollution on susceptible populations, Regulatory issues in inhalation, Biology and Physics problems in pulmonary drug delivery and Systemic Delivery via the lung to treat PAH and Pain.

For registration and information about the conference, please visit our website: www.ISAM2009.com. Early registration ends March 10th, 2009 (http://www.isam2009.com/main.cfm?cid=1333&nid=11367)
The meeting abstract deadline is February 15th, 2009 (http://www.isam2009.com/main.cfm?cid=1333&nid=10995).
We are actively seeking sponsors for the Congress to help support ISAM. Please contact Terry Sweeney (tsweeney@nektar.com) or Ralph Niven (rniven@aptbio.com) for more information.
Exhibitor space is available at the meeting. Please contact David Cipolla (cipollad@aradigm.com) for more information.

You won't want to miss the scientific interchange, beautiful locale, and the banquet to be held at the renown Monterey Bay Aquarium (http://members.montereyinfo.org/montereybayaquarium/). It is truly a special location and promises to be an evening to remember.

We look forward to your participation and to seeing you in Monterey!

The ISAM 2009 Organizing Committee,
Terry Sweeney, Jim Blanchard, Ralph Niven, and David Cipolla

NorCal SOT newsletter February 2009


Dr. Xiao Jiang Tang

An Interview with Two Scholars from UC Berkeley - by Tao Wang

At the NorCal SOT symposium last fall, I met Dr. Xiao Jiang Tang and Dr. Xue Feng Ren, both of whom were research scholars from UC Berkeley at that time. After the meeting, I had an opportunity to chat with them. Both Dr. Tang and Dr. Ren gave me a lot of valuable suggestions and ideas regarding NorCal SOT activities. Here is the interview:

Q: Have you been coming to the Spring and Fall meetings held by NorCal SOT? How do you like them?

Dr. Tang: I have attended all the recent meetings held by NorCal SOT. You guys have been doing a great job on organizing these meetings! As a research scientist, I found that the spring meeting on "Developmental Neurobehavioral Toxicology" regarding fetal alcohol syndrome was quite fascinating. I understand that the fall symposium on Safety Pharmacology Testing is more for industry people, it is good too.

Q: Is there anything you would like to see in our future meetings? Or any improvement you think that we can do?

Dr. Tang:I think it is a good idea to have regulatory people from FDA or EPA to give some talks. For example, at the spring meeting, you guys invited a speaker from the US EPA, and she talked about when and how neurotoxicity testing is conducted, and the use of the data in risk assessment. I found the up-to-date information from EPA quite useful. It is good for us to know the guidelines or the current trend and directions set by the regulatory agencies. [Dr. Virginia (Ginger) Moser from EPA presented "Guideline developmental neurotoxicity testing for risk assessment" at our spring meeting]

Q:What do you guys think about other activities during the meeting other than the symposium, for example, the "meeting with expert" lunch, the student awards?

Dr. Ren: The student awards were very good for us. It gives us a chance to communicate our research to the toxicologists in the bay area, and to have more interaction with the professionals. I like it very much. I will apply for the award next time. The "meeting with expert" lunch is good for students to network with professionals, and to obtain helpful information.

Q: What can NorCal SOT do to further help our students and postdocs in the bay area? To increase communications with you guys?

Dr. Tang:When you guys hold local meetings, maybe not only the students, postdocs, and research scientists can display posters, but the NorCal SOT board can have a poster too. You can use the poster to further communicate your missions, activities in the toxicology field around the bay area, and job openings - not only for students, but for all members.

Dr. Ren: As a graduate student in the past, and a postdoctoral fellow now, I felt that although there are career seminars and "meeting with expert" lunches, we still do not have a good concept of what having a toxicology job in industry really means. What is your day look like as a toxicologist working for, say a biotech company? This is something maybe you can use your newsletter, like a case study, to help us learn more about the jobs in the toxicology field.

It was a very pleasant and helpful conversation. At the end, I thanked Dr. Xiao Jiang Tang and Dr. Xue Feng Ren for the valuable information they had provided. Dr. Tang has now finished his research work at UC Berkeley, and returned to China. He is currently working at Guangdong Prevention and Treatment Center for Occupational Diseases. NorCal SOT wishes him the best! Dr. Ren is still doing his research at UC Berkeley. Dr. Ren just won the 2009 Postdoctoral Fellowship Award from the SOT Carcinogenesis Specialty Section. Congratulations to Dr. Ren!!

As one of the results of this interview, we added a "Career Corner" in our newsletter. In this issue, we invited Jeff Tepper, a seasoned consultant in the toxicology field in the bay area, to write about his job as a toxicology consultant, and what he does on a daily basis. We hope his story will help our students, postdoctoral fellows, and even young toxicology professionals to better understand this field. Jeff has also graciously agreed to give his contact information. If you have questions or want to know more about this career, he is happy to help you out.

Dr. Xue Feng Ren

NorCal SOT newsletter
February 2009



Are you interested in being a toxicology consultant? It was a career path that I had been thinking about for a number of years. Finally, over a year ago, I took my first steps towards consulting as a full time occupation. By way of introduction, I've been working in the pharmacology/toxicology arena for more than 25 years. My skills were honed as a Research Scientist working with the US EPA, a Senior Scientist in the Immunology Dept. at Genentech, the Director of Pharmacology at Bayer Biotechnology, a VP of Pharm/Tox at Catalyst BioSciences and as a Co-Founder of Aerovance, a biotech company. During those years, I also had the opportunity to serve as a consultant to various government, academic, contract research organizations and biotech companies. But in those jobs, it was always "in addition" to my regular full time job. So despite those experiences, I was still nervous about whether I could "make it" as a consultant. This is called "consultant's angst," as I learned at a great course offered by the Round Table of Toxicology Consultant's (RTC). Most consultants, even those with many years of experience, still feel it. It is primarily the concern of when the next job will come.

Other than worry, what do toxicology consultants do? So far, what I've been doing is helping companies design, implement and oversee their pharmacology/toxicology programs, as well as, writing and reviewing reports, publications, investigator brochures and INDs. I've also been involved in troubleshooting problems with studies, impurities and helping select delivery devices. Really, I do pretty much the same kind of work that I did when I was at a company, except that now the work comes from many companies. It is learning about new products, new indications and meeting new people that I find so exciting about this career. I have toxicology consultant friends who also work on legal cases, but I've not tried that yet. However, as a consultant, I think you need to be prepared to do anything a client wants, as long as you feel it is within your scope of knowledge (or you have knowledgeable friends who are willing to help!). I've always tried to be very upfront with clients about what I can and can't do.

As in any job, being a consultant has its pros and cons. First, it does require diligence, because it can be easy to find distractions when working from home. Since I had worked from home at least one day a week for the last seven years, I was pretty sure that wouldn't be too much of a problem. Having a comfortable chair and being cozy with your computer are necessities. I find that I spend most of my day either reading or typing into my computer. Most communication transpires via e-mail, with only limited human interaction. Being an extrovert, the lack of communication with people on a regular basis has been a downside for me. To combat loneliness, I try to spend some time each day networking. Having flexible work hours is great, but you need to be very mindful of client deadlines and crunch periods. Since your business is almost solely dependent on your reputation, it is best if your client's schedule is your schedule. I do miss seeing projects/programs come to a conclusion, but if you do a good job, your clients may reappear allowing you to find out what happened. You can do a lot of traveling if you want, but I know consultants who claim to never travel. People always seem to be interested in how much money consultants make. In a survey taken by the RTC, the median income of 79 established consultants was between $150,000 and $200,000 (of course, your results may vary). Overall, I'm enjoying my experience and would be happy to chat with anyone about different careers in toxicology. You can contact me at TepperTox@aim.com or check out my website: www.TepperTox.com.

NorCal SOT newsletter
February 2009

Research at UC Davis: Series II

by Susanne Brander

In November 2007, over 50,000 gallons of oil spilled into the San Francisco Bay when the Cosco Busan cargo ship collided with a Bay Bridge support. As a result, miles of rocky intertidal coastline, sandy beach, saltmarsh, and eelgrass beds - which are important nurseries for herring - were oiled. In some cases habitat recovery may take up to five years.

The potential impact of this spill on local herring populations is now being assessed at the University of California, Davis, Bodega Marine Laboratory (BML), in Dr. Gary Cherr's laboratory. Dr. Cherr is a professor in the Departments of Environmental Toxicology and Nutrition at UC Davis. The study is co-led by Drs. Cherr, John Incardona and Nathaniel Scholz of the National Oceanic and Atmospheric Administration's (NOAA) Northwest Fisheries Science Center (Seattle, WA).

Assessment of herring embryo health is part of a larger effort seeking to assess and quantify the ecological damage resulting from the spill, through a collaboration of state and federal trustee agencies participating in a process known as "natural resource damage assessment" (NRDA).

Herring, which are known to be highly sensitive to perturbations such as pollutants and habitat loss, were chosen to measure the impact on aquatic organisms in the SF Bay. Also, in an unfortunate coincidence, the herring spawning season occurred shortly after the spill in 2007.

Initial results from the ongoing studies at BML found that herring eggs from the spill zone showed abnormalities that would lead to death, while eggs from areas unaffected by the spill were largely normal. According to an article published on the study in the Santa Rosa newspaper The Press Democrat last year, exposure to small amounts of petroleum hydrocarbons can cause an erratic heartbeat or swelling and malformation of the heart. Discerning whether these abnormalities are directly linked to the spill will require further research, as will determining what the potential lost contribution to the overall SF Bay herring population is.

In the meantime, specific areas important to herring as spawning and nursery sites, such as Kiel Cove (pictured), are being proposed for restoration. The NRDA trustees will be hosting public meetings to present study results and to solicit ideas for restoring damaged areas in the near future.

For a recent interview with Dr. Gary Cherr regarding the research:

http://www-bml.ucdavis.edu/geninfo/bml_news.html

For further information on Trustees:

http://dfg.ca.gov/ospr/spill/nrda/nrda_cosco-busan.html
http://darrp.noaa.gov/southwest/cosco/index.html
www.fws.gov/contaminants/Issues/OilSpill.cfm
http://www-bml.ucdavis.edu/geninfo/bml_news.html



developing herring eggs

In The Press … Recent Publications !!

SOT Member Names Are In Red

Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. **Clemens GR**, Schroeder RE, Magness SH, Weaver EV, Lech JW, Taylor VC, Masuda ES, Baluom M, Grossbard EB. Birth Defects Res A Clin Mol Teratol 85(2):130-136.
:
Characterization of liver injury associated with hypersensitive skin reactions induced by trichloroethylene in the guinea pig maximization test. **Tang X**, Que B, Song X, Li S, Yang X, Wang H, Huang H, Kamijima M, Nakajima T, Lin Y, Li L. J Occup Health. 2008 Mar;50(2):114-21.

Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water. Kenyon EM, Hughes MF, Adair BM, Highfill JH, Crecelius EA, Clewell HJ, **Yager JW.** Toxicol Appl Pharmacol 232:448-455, 2008.

Guidelines for derivation of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Hays SM, Aylward LL, LaKind JS, Bartels MJ, Barton HA, Boogaard PJ, Brunk C, DiZio S, Dourson M, Goldstein DA, Lipscomb J, Kilpartick ME, Krewski D, Krishnan K, Nordberg M, Okino M, Tan Y-M, Viau C, **Yager JW.** Reg. Toxicol. Pharmacol. 51: S4-S15, 2008.

Guidelines for the communication of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. LaKind JS, Aylward LL, Brunk C, DiZio S, Dourson M, Goldstein DA, Kilpartick ME, Krewski D, Bartels MJ, Barton HA, Boogaard PJ, Lipscomb J, Krishnan K, Nordberg M, Okino M, Tan Y-M, Viau C, **Yager JW**, Hays SM. Reg. Toxicol. Pharmacol. 51: S16-S26, 2008.

Biomonitoring Equivalents (BE) dossier for cadmium (Cd) (CAS No. 7440-43-9). Hays SM, Nordberg M, **Yager JW**, Aylward LL. Reg Toxciol Pharmacol 51:S49-S56, 2008.

Toxicity of a dissolved pyrethroid mixture to *Hyalella azteca* at environmentally relevant concentrations. **Brander SM**, Werner I, White JW, Deanovic LA. Environmental Toxicology and Chemistry (in press)

NorCal SOT newsletter February 2009

2009 NorCal SOT Young Investigator Award

This year, the Award Committee received total of six applications. All six applicants have very strong research backgrounds and excellent supporting letters from their mentors. The selection of awardees was based on not only the abstract, but also the significant impact of his/her work on toxicology, and a supporting letter from his/her mentor. It was very tough for the Award Committee to choose the top candidates for the awards. First of all, let us applaud the hard-working judges on the Award committee, and they are:

CONGRATULATIONS!!

Susan Rice, PhD, DABT
Susan A Rice and Associates (past President)

Jane Gunther, PhD, DABT
Elan Pharmaceuticals

Tao Wang, MD, PhD, DABT
Novartis

Each award includes a plaque, and a cash award that will support the awardees to attend the upcoming SOT Annual Meeting in Baltimore. After much deliberation from the Award Committee, instead of giving two awards as planned, the Award Committee and NorCal SOT Board have decided that three candidates will be given the awards, as the competition was very tight. Therefore, the awards go to:

Zhiying Ji

First Place: The benzene metabolite, hydroquinone alters global DNA methylation and specific gene promoter methylation in human TK6 cells
From his mentor, Dr. Ji "is an outstanding, highly energetic researcher who is extremely hard working. In his first year with me he showed his creative potential..... In his second year... he devoted to collecting samples for projects...He worked more than 12 hours every day and continuously worked 2 months without a single day off. He was the backbone of the field team... "
From the Award Committee, "Dr. Ji's research involves both the development of several novel lab techniques and field work, he is a researcher that sees the application of his work outside of the lab. Dr. Ji demonstrates leadership qualities, important for a new investigator, as the backbone and key to success of the field team in China and in the lab as the point person of epigenetics". And more, "the abstract is the cleanest with no confusing or ambiguous statements".

Second Place: Alteration of H4K16 acetylation via Sas2 in yeast and MYST1 in humans is associated with increased sensitivity of arsenic toxicity
From the Award Committee: This is a mechanistic study using state of the art techniques. This work has been submitted for publication and is under consideration by the high impact Journal of Biological Chemistry. This candidate is currently writing an invited review on arsenic epigenetics and has also submitted a research paper to Genome Biology on arsenic susceptibility traits. His mentor commented that "He is an outstanding, highly energetic researcher who has been enormously productive in the past year." This work has also won Dr. Ren the 2009 Postdoctoral Fellowship Award from the national SOT Carcinogenesis Specialty Section.

Xuefeng Ren

Third Place: Utilizing functional genomics in yeast to discover novel biomarkers of benzene toxicity in humans
From the Award Committee: He states that his yeast technique of parallel deletion analysis can be applied rapidly to many different toxicants, many of which have no toxicological data so his work has the potential to significantly add to our knowledge of chemical susceptibility genes and impact public health. He has shown creativity when "several of his results lead in unexpected directions","he developed and tested hypotheses for his observations". According to his PI, Dr. North demonstrates leadership qualities, important for a new investigator, taking the lead in overseeing "our research" into the identification of biomarkers of human susceptibility to benzene and its metabolites". As well as being a "patient teacher and mentor".



Matthew North

NorCal SOT newsletter
February 2009

Post-Doctoral Initiative

by Valerie Mitchell

For the first time NorCal SOT is including the position of a Postdoctoral Representative to the board. Representatives will be members of SOT in good standing and scheduled to remain in a mentored postdoctoral research position for at least half of their term. We are currently soliciting volunteers to fill this position for 2009. The Society of Toxicology has made great strides to recognize the importance of postdoctoral fellows in the field of toxicology. The Postdoctoral Assembly (PDA) was created to assist SOT with its long term goals, which include increasing postdoctoral membership and participation in the Society, and assisting with the professional development of postdoctoral members. One goal of the PDA board is to actively promote postdoctoral representation and participation within the SOT Committees, Regional Chapters, Specialty Sections and Special Interest Groups.

Currently, the PDA board consists of a Chair (Heather Floyd), Vice Chair (Betina Lew), Secretary/Treasurer (Valerie Mitchell), Councilor (Lauren Aleksunes), a Liaison appointed by Council (Ronald Hines), and a Staff Member from SOT Headquarters (Betty Eidemiller). Recently the PDA approved a change to the structure of the PDA board. The change included splitting the Secretary/Treasurer position into two separate positions. In addition, the Secretary now serves two years on the board. Previously only the Vice Chair had a two-year term, advancing to the position of Chair in the second year. This change will increase continuity within the board. The change has been implemented in the election of the 2009-2010 board. Nominations have been gathered and the election for the new PDA board will take place the end of February. The winners will be introduced at the postdoctoral luncheon at the annual meeting in Baltimore.

The achievements of the current board include co-sponsorship of an informational session with the Student Advisory Council entitled "Gene-Environment Interactions: Epigenetic Pathways in Chronic Disease Promotion and Progression" featuring scientific talks exclusively by postdoctoral fellows and senior graduate students, as well as an Education-Career Development Session co-sponsored with the Toxicologists of African Origin Special Interest Group entitled "Career Opportunities and Transitions in Toxicology" at the 2009 Annual Meeting in Baltimore, MD. In addition the PDA sponsors an annual Best Postdoc Publication Award (BPPA). The applicants are first reviewed by the PDA board and then by members of council. The top three papers are awarded a plaque and $100. The winners will be announced at the Postdoctoral Luncheon in Baltimore. The luncheon is a great opportunity to network with fellow postdocs and provide important feedback to the PDA on initiatives that are important to you. Both of the PDA sessions featured at the 2009 annual meeting were a result of feedback provided at last year's luncheon as well as in the 2008 Survey of the Postdoctoral Experience. All postdocs are encouraged to attend the luncheon. The luncheon is a ticketed event so please make sure to sign up when registering for the annual meeting. We look forward to seeing everyone in Baltimore!

2008-2009 NorCal SOT Board of Directors

President:	**George Clemens, Rigel Pharmaceuticals, South San Francisco gclemens@rigel.com (650) 624-1377**
Vice President:	**Stephen Dizio, Department of Toxic Substances Control, Sacramento, sdizio@dtsc.ca.gov**
Vice-President Elect:	**Tao Wang, Novartis Pharmaceuticals, Emeryville tao.wang@novartis.com (510) 923-3562**
Secretary:	**Charles Barton, Xoma, Berkeley barton@xoma.com (510) 204-7553**
Treasurer:	**Jeffrey S Tepper, Consultant TepperTox@aol.com www.TepperTox.com**
Councilor: (Past President)	**Sanjay Chanda, Anacor Pharmaceuticals, Palo Alto schanda@anacor.com (650) 543-7592**
Councilor:	**John A Wisler, Amgen, South San Francisco jwisler@amgen.com (805) 447-9787**
Councilor:	**Karen Steinmetz, SRI International, Menlo Park karen.steinmetz@sri.com (650) 859-4145**
Student Liaison:	**Susanne Brander, UC Davis, Bodega Marine Lab smbrander@ucdavis.edu (707) 227-0384**

Genentech
IN BUSINESS FOR LIFE

For more than 30 years, Genentech has been at the forefront of the biotechnology industry, using human genetic information to develop novel medicines for serious and life-threatening diseases. Today, Genentech is among the world's leading biotech companies, with multiple therapies on the market for cancer and other unmet medical needs. Please take this opportunity to learn about Genentech, where we believe that our employees are our most important asset.

We have an opportuniies available in our South San Francisco, CA facility for a:

Investigative Safety Assessment Scientist/Senior Scientist

Position Description and Responsibilities
The Department of Safety Assessment at Genentech provides scientific leadership and plays an active role in the process of drug development from the discovery period through marketed products.

We are seeking a Scientist/Senior Scientist in the Department of Safety Assessment (Investigative Safety Assessment Group) to support drug discovery and development. This role will involve working in a collaborative team environment as part of the comprehensive safety assessment of Genentech therapeutics by providing toxicology representation to small molecule discovery programs and proactive issue investigation for all molecular platforms (i.e. small molecules, large molecules, antibody-drug conjugates).

Responsibilities
The successful candidate will serve as a safety representative on project teams during the discovery phase and interact closely with discovery scientists and Safety Assessment development (regulatory) toxicologists and pathologists to provide better candidate selection and characterization of toxicology issues at the time of transition to early development. In this role, the key deliverables will include proactive risk assessment of potential toxicity issues related to undesired or exaggerated pharmacology; investigation or characterization of potential toxicity issues; and strategic advisement with regard to safety considerations unique to the therapeutic target, the disease target population and the competitive landscape.

The successful candidate will also design, implement and supervise toxicology studies in support of compound lead optimization (e.g. in vitro toxicity screening, counter-assay development) and mechanistic investigations (development of hypothesis-driven research plans, in vitro or in vivo model development and qualification, and scientific project management), and contribute to continual innovation through the identification and application of new technologies or approaches. This will include supervision and training of technical staff as necessary.

Requirements
Applicants should have a PhD or DVM and post-doctorate or equivalent experience in toxicology or a relevant field, with at least 4 years relevant experience in the pharmaceutical/biotechnology/CRO industry related to toxicology. Candidates with experience in the discovery toxicology setting are preferred, as are those with experience supporting immunology and neurobiology therapeutic areas.
Qualified candidates must demonstrate strong decision-making, complex problem-solving, critical data analysis and interpretation, and investigative skills; have a strong theoretical/practical knowledge and technical abilities in the enzyme and /or cell-based assays, in vitro/ex vivo method development and state-of-the-art molecular biology (e.g. systems biology platforms, reporter assay development, siRNA); excellent written and verbal communication skills; and the ability to build productive cross-functional collaborations both within and external to Genentech.

Senior Scientist - Toxicologist

The Safety Assessment department of Genentech is seeking a Sr. Toxicologist with a proven record of drug development and leadership in the area of small molecule pharmaceuticals. As the Sr. Scientist for the Small Molecule Therapeutics you will lead a highly talented team of toxicologists in a fast-paced environment to create and execute highly integrated drug development strategies in support of new molecular entities from late-stage research through licensure and life-cycle management. As a Sr. Scientist you may also be a PSTL (Pharmacology Sub Team Leader), leading the overall direction of the pharmacology effort (PK/PD, Safety Assessment, Metabolism, and Biological Assay & Characterization) to support the development, approval, and commercialization of the product.

The successful candidate will be a recognized leader and contributor to the small molecule safety assessment field, with a passion for bringing new medicines to patients with unmet medical needs, and dedication to teamwork, collaboration, innovation and staff development. Toxicologists at Genentech provide scientific leadership and play an active role in the process of drug development. Working in an integrated and collaborative team environment, we lead the safety assessment of Genentech therapeutics by creating a best-evidence synthesis of existing knowledge and comprehensive characterization of toxicologic activity. In addition to providing strategic vision for the development of our rapidly expanding small molecule drug development portfolio, position responsibilities include: staffing, mentoring, and career development of toxicologists and research associates, scientific leadership in the design and implementation of safety assessment strategies for Genentech's small molecule portfolio, and leading or providing support to inter- and intra-departmental initiatives. This is an excellent opportunity for a senior level toxicologist, with strong scientific, communication, and teamwork skills, who is committed to bringing innovative therapies to patients. This position will report to the Associate Director of Toxicology in the department of Safety Assessment.

Requirements

Dynamic, creative individual with an established record of experience and accomplishment in driving drug development and safety assessment for small molecule (and/or biological) pharmaceuticals. Demonstrated understanding of the drug development process. Excellent interpersonal, written and verbal communication skills. The ability to work with others in a helpful, collaborative and respectful manner while simultaneously building credibility and rapport. Evidence of significant contribution to the field, and direct interaction with regulatory authorities. Must display strong team leadership/ management skills, effective decision making capabilities and the ability to motivate and influence others. Proven ability to build and sustain productive internal and external cross-functional collaborations a must.

Education
PhD or equivalent experience in toxicology with 8+ years professional experience in the pharmaceutical industry. Board certification in toxicology highly desirable.

Manager, Study Monitors

We are seeking a highly motivated individual with exceptional communication and organizational skills, scientific training, significant knowledge and experience of drug development, pre-clinical study monitoring and management. This individual will represent the Study Operations Group on cross functional Project Teams, supervise direct reports, serve as a key liaison between different functional groups and monitor non-clinical studies for selected studies/projects, serving as the single point of contact for all study-related requirements (GLP and non-GLP) that have been contracted to external Contract Research Organizations (CROs); in addition to contributing to Regulatory submissions, according to all applicable regulations and Genentech Standard Operating Procedures (SOPs).

Responsibilities to include:

Study Management
•Develop and streamline processes to maximize efficiency in the execution of non-clinical studies.
•In partnership with Genentech investigators and CROs: design, implement and interpret various types of complex non-clinical studies that support all phases of drug development.
•Able to assist senior personnel in identifying and definine critical study and project tasks.
•Ability to make sound and timely decisions based on study needs, foresee and circumvent problems, develop and refine procedures to advance Genentech's therapeutic candidates.
•Collaborate with internal and external contacts and resolve study-related issues as they arise.

Relationship Management
•Build and maintain relationships with internal stakeholders and external vendors.
•Actively identify and develop new relationships which would add value and be beneficial to GNE's business.

People Management
•Oversight, mentoring and training of direct reports.
•Commitment to career development for self and direct reports

Compliance and Regulatory
•Identify and implement process improvements with respect to study execution and documentation in conjunction with Quality Assurance Unit.
•Develop and review SOPs.
•Maintain communication with CROs to assure studies are conducted in compliance with the protocol, GLP (if applicable), SOPs, and overall non-clinical objectives.
•Assist in preparation of reports for regulatory submission.

Requirements:
•BS/BA/MS/ PhD in toxicology/pharmacology/immunology/PK/ biological sciences or related field. Minimum of 8 years management experience. Hands on experience with in vivo studies, performance of GLP studies or equivalent combination of education and experience.
•Exceptional interpersonal, organizational and problem-solving skills.
•Acute understanding of corporate objectives, the vision and ability to work with internal and external resources to focus on and realize corporate goals.
•Detail oriented and able to multi-task.
•Team player but also strong individual contributor.
•Works well under time and pressure constraints.
•Travel required up to 25% of the time.

Associate Scientist - Toxicologist

The Safety Assessment division of Genentech is seeking a toxicology scientist. Toxicologists at Genentech provide scientific leadership and play an active role in the process of drug development from late-stage discovery through marketed products. Working in a collaborative team environment, we lead the safety assessment of Genentech therapeutics by creating a best-evidence synthesis of existing knowledge and comprehensive investigations of toxicologic activity. The successful candidate will design and supervise in vitro and in vivo toxicology studies primarily for small molecules, work closely with Study Monitors, Pathologists and Pharmacokineticists to deliver high quality GLP and non-GLP in vivo study reports and, as needed, represent Genentech in meetings with regulatory authorities. Responsibilities include interdisciplinary project team membership, preparation and review of regulatory documentation, study reports and manuscripts, participation in toxicology and pharmacology initiatives, and other active cross-functional collaborations.

Requirements

Excellent written and verbal communication skills. Capability to build productive cross-functional collaborations both within and external to Genentech.

Education

PhD or equivalent experience in toxicology with at least 2 to 4 years experience in the pharmaceutical/biotechnology/CRO industry. Board certification in toxicology desirable.

Interested candidates, please email resume to Maguire.
Sherry@gene.com

Genentech is dedicated to fostering an environment that is inclusive and encourages diversity of thought, style, skills and perspective.

Genentech is an Equal Opportunity Employer.

Principal Investigator-Immunology
Job #100032
Biosciences Division

SRI International, an independent non-profit organization founded as the Stanford Research Institute in 1946, is a leader in the development of new products for the treatment and diagnosis of disease, primarily in the areas of cancer, infectious disease, neuroscience, and immunology. SRI's Biosciences Division (www.sri.com/biosciences) works in several ways, conducting basic research like an academic institution, performing drug discovery and biologic development like a biotechnology company, and carrying out preclinical development and pharmaceutical services like a contract research organization – from "Idea to IND"TM.
The Division works with partners and clients on a broad range of preclinical discovery and development projects, utilizing its expertise in medicinal chemistry, custom organic synthesis, efficacy pharmacology and safety evaluation, pharmacokinetics and metabolism studies, analytical chemistry, formulation design, drug product manufacturing, project management and regulatory affairs. Many studies are conducted under FDA's GLP and GMP regulations. SRI currently has several drugs on the market, several more in clinical trials, half a dozen in preclinical development, and has assisted in the development of more than 130 other products that made it to clinical trials or reached the market.

The Immunology and Inflammation Center in the Biosciences Division at SRI International seeks well qualified applicants for a Principal Investigator level position to study cellular and molecular immune responses. The successful candidate will be expected to pursue independent as well as collaborative studies and will plan, direct and maintain a creative and productive research program. Moreover, experience as group-leader, excellent publications, above-average fund-raising, as well as experience in working abroad and collaboration-willingness are expected.

Qualifications:

Qualified candidates must have a Ph.D. with a strong background in cellular signaling and/or molecular mechanisms of immunity, and at least four years of postdoctoral experience. Selection will be based on excellence in research and proven ability to develop an outstanding independent research program. The position requires close collaboration with the other scientists (staff, postdocs scientists) in the group.

Current Extramural Funding is preferred.

Post-offer, pre-laboratory physical examination is required.

How to apply:
Apply via our web page: www.sri.com/jobs to job number 100032

SRI is an equal opportunity employer.
www.sri.com